The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
DICERNA PHARMACEUTICALS INC COM 253031108 105,262 7,330,237 SH   SOLE   7,330,237 0 0
MARINUS PHARMACEUTICALS INC COM 56854Q101 7,766 5,042,735 SH   SOLE   5,042,735 0 0
REPLIMUNE GROUP INC COM 76029N106 39,462 2,838,968 SH   SOLE   2,838,968 0 0
SOLID BIOSCIENCES INC COM 83422E105 40,028 3,871,164 SH   SOLE   3,871,164 0 0
APTINYX INC COM 03836N103 7,766 2,225,092 SH   SOLE   2,225,092 0 0
SPRINGWORKS THERAPEUTICS INC COM 85205L107 157,859 7,281,307 SH   SOLE   7,281,307 0 0
DYNAVAX TECHNOLOGIES CORP COM 268158201 30,259 8,452,235 SH   SOLE   8,452,235 0 0